Loading...
•
Jun 30
Aurinia Q2 2025 Earnings Report
Aurinia reported strong Q2 2025 results with year-over-year revenue growth and a return to profitability.
Key Takeaways
Aurinia posted $70 million in revenue and $21.5 million in net income for Q2 2025, supported by solid LUPKYNIS sales. The company also improved operating cash flow and announced expanded share repurchase plans.
Total revenue for Q2 2025 was $70 million, up from $57.2 million a year ago.
LUPKYNIS product sales reached $66.6 million in the quarter.
Net income improved to $21.5 million compared to $0.7 million in Q2 2024.
The company repurchased 11.2 million shares for $90.8 million in the first half of 2025.
Aurinia
Aurinia
Aurinia Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comLicense & Royalty Revenue
CapyFin.com Forward Guidance
Aurinia raised its full-year 2025 guidance for both total revenue and net product sales due to continued LUPKYNIS growth and favorable treatment guidelines.
Positive Outlook
- Total revenue guidance raised to $260–$270 million.
- Net product sales guidance increased to $250–$260 million.
- Strong uptake driven by updated lupus nephritis treatment guidelines.
- Positive Phase 1 data for AUR200 (aritinercept).
- Healthy liquidity position with $315.1 million in cash and investments.
Challenges Ahead
- Cash and investments declined from $358.5 million at year-end.
- No adjusted EPS reported for the quarter.
- Ongoing expenses related to restructuring and R&D.
- SG&A expenses remained high at $26 million for the quarter.
- Limited geographic breakdown of revenue reported.